Purespring Therapeutics
London
About Purespring Therapeutics
Purespring Therapeutics is a pioneering company focused on developing gene therapies for various kidney diseases, particularly targeting podocytes, which are specialized kidney cells. The company is among the first globally to employ AAV gene therapy specifically for kidney conditions, aiming to tackle one of the most challenging areas in medicine.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $164.1M
- Funding stage: Early Stage Venture
- Last round: Series B (Oct 2024)
- Website: purespringtx.com
- Phone: +44 (0)20 3855 6324
Industries & Categories
Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/purespring-therapeutics-19608 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.